Merck (NYSE:MRK) - Cotización, noticias y análisis

Resumen de acción MRK

Merck & Co., Inc. opera como empresa sanitaria en todo el mundo.

MRK fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	4/6

Recompensas

Cotiza un 52.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 26.29%

Análisis de riesgos

Tiene un alto nivel de endeudamiento

El dividendo de 2.36% no está bien cubierto por los beneficios

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (3.8%) son inferiores a los del año pasado (22.5%)

+ 1 riesgos adicionales

Narratives

Beta

Narratives bring a range of perspectives from our community.

Warren

Based on Analyst Price Targets

Strategic Expansions and Diversifications Poised to Propel Revenue Growth

Merck's strategic acquisitions and collaborations, notably with Prometheus and Daiichi Sankyo, aim for long-term gro...

Price at publication US$129.45

View narrative

Updated 19 Feb 2024

Competidores de Merck & Co., Inc.

Johnson & Johnson

NYSE:JNJ

US$353.8b

Pfizer

NYSE:PFE

US$143.0b

Eli Lilly

NYSE:LLY

US$652.9b

Bristol-Myers Squibb

NYSE:BMY

US$99.3b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share Price	US$130.72
52 Week High	US$133.10
52 Week Low	US$99.14
Beta	0.40
1 Month Change	4.14%
3 Month Change	8.19%
1 Year Change	13.51%
3 Year Change	77.42%
5 Year Change	64.39%
Change since IPO	11,519.56%

Noticias y actualizaciones recientes

Recent updates

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

Apr 17

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Apr 09

Merck: Better Times Ahead On Approvals And Outlook

Apr 02

Merck's Future Brightens With Winrevair's Blockbuster Potential

Mar 27

Merck: A High-Conviction Investment For Long-Term Growth

Feb 29

Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings

Jan 29

Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?

Jan 26

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Jan 08

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

Dec 25

Rentabilidad de los accionistas

	MRK	US Pharmaceuticals	Mercado US
7D	4.4%	-0.6%	1.0%
1Y	13.5%	10.6%	21.9%

Rentabilidad vs. Industria: MRK superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 10.6% el año pasado.

Rentabilidad vs. Mercado: MRK obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: MRK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MRK (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1891	71,000	Rob Davis	www.merck.com

Merck & Co. opera como empresa de asistencia sanitaria en todo el mundo. Opera a través de dos segmentos: Farmacéutico y Salud Animal. El segmento Farmacéutico ofrece productos farmacéuticos para la salud humana en las áreas de oncología, cuidados agudos hospitalarios, inmunología, neurociencia, virología, cardiovascular y diabetes bajo las marcas Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi y Januvia, así como productos vacunales consistentes en vacunas preventivas pediátricas, para adolescentes y adultos bajo las marcas Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23 y Vaqta.

Resumen de fundamentos de Merck & Co., Inc.

¿Cómo se comparan los beneficios e ingresos de Merck con su capitalización de mercado?
Estadísticas fundamentales de MRK
Capitalización bursátil	US$331.12b
Beneficios(TTM)	US$2.31b
Ingresos (TTM)	US$61.40b

143.6x

Ratio precio-beneficio (PE)

5.4x

Ratio precio-ventas (PS)

¿Está MRK sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MRK
Ingresos	US$61.40b
Coste de los ingresos	US$15.53b
Beneficio bruto	US$45.87b
Otros gastos	US$43.57b
Beneficios	US$2.31b

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Jul 30, 2024

Beneficios por acción (BPA)	0.91
Margen bruto	74.71%
Margen de beneficio neto	3.76%
Ratio deuda/patrimonio	93.1%

¿Cómo se ha desempeñado MRK a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.4%

Rentabilidad actual por dividendo

241%

Ratio de pagos

Resumen de acción MRK

Recompensas

Análisis de riesgos

Strategic Expansions and Diversifications Poised to Propel Revenue Growth

Competidores de Merck & Co., Inc.

NYSE:JNJ

US$353.8b

NYSE:PFE

US$143.0b

NYSE:LLY

US$652.9b

NYSE:BMY

US$99.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

Recent updates

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Insider notifies of intention to sell stock

Insider exercised options and sold US$1.7m worth of stock

Executive VP & General Counsel recently sold US$3.8m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 16%

Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Third quarter dividend of US$0.77 announced

Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Merck & Co., Inc.

143.6x

5.4x

Beneficios e Ingresos

Dividendos

2.4%

241%